Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Overweight rating on Twist Bioscience (NASDAQ:TWST) and raises the price target from $20 to $26.
August 07, 2023 | 10:44 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst maintains an Overweight rating on TWST and raises the price target from $20 to $26.
The news is directly related to TWST as Barclays analyst has maintained an Overweight rating on the company and raised the price target. This indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100